Following a High Court case won by twelve NHS Clinical Commissioning Groups (CCGs) in favor of prescribing the significantly cheaper anti-vascular endothelial growth factor (anti-VEGF), Avastin (bevacizumab), over Novartis’ and Bayer’s licensed anti-VEGF eye drugs,

Edit Kovalcsik, Managing Pharma Analyst at GlobalData, a leading data and analytics company, offers her view on the likely outcome of the NHS victory:

“Wet age-related macular degeneration (AMD) is effectively managed by anti-VEGF therapies; however, approved medications, Roche/Novartis’ Lucentis and Regeneron/Bayer’s Eylea, are highly priced, reaching around £5000 per patient annually. Avastin, also Roche’s anti-VEGF, approved for metastatic colorectal cancer but not for ophthalmology, is widely used off-label for wet AMD, particularly in the US.

“Avastin is a much cheaper alternative, costing only a small fraction of the approved drugs for wet AMD treatment, less than £400 a year per patient; however, the UK government ruled out the routine use of Avastin in 2015.

“Based on GlobalData’s primary research, in the US around 50% of patients with wet AMD are prescribed Avastin, because the majority of payers, including the US Medicare, reimburse Avastin while ophthalmologists often need to obtain prior authorization if they want to prescribe the approved anti-VEGFs. As a result, the UK represented the second largest AMD market among the seven major markets (7MM*) in 2016, according to GlobalData’s report: ‘Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2026’.

IMAGE FOR PUBLICATION: Please click link for chart: ‘Drug Sales by Country for AMD in the 7MM, 2016 – 2026′

“Lucentis is derived from the larger parent molecule, bevacizumab, developed by the same company, Genentech, subsidiary of Roche. There was a hope that Lucentis, as a lower-molecular-weight, humanized fragment of an immunoglobulin G1 (IgG1) mAb, would result in improved retinal penetration over Avastin, and therefore confer superior efficacy and cause less inflammation.

“Despite Lucentis’ stronger binding ability to the VEGF protein, however, clinical trials comparing the two drugs for AMD, the CATT trials, sponsored by the National Institutes of Health (NIH), reported in 2012 that the two drugs had similar efficacy and safety. Furthermore, the UK National Institute for Health Research (NIHR)-funded study, named IVAN, also found the two treatments equivalent in efficacy and safety.

“Many of the UK’s CCGs asked the government and NICE to provide a specific exception to their standard guidance to support the use of Avastin in wet AMD on the basis of clinical safety and cost effectiveness, claiming that this would dramatically cut costs for the NHS; but the UK government did not allow this due to its regulations over the use of off-label drugs for the safety of the patients.

“Having developed a new, more expensive drug; however, it is unlikely that the companies would apply for a licence of Avastin in wet AMD, even though Lucentis was not proved to be more effective or safer than its original version. In addition, Avastin’s patent will expire next year, further reducing the cost of this drug.

“As a result of NICE’s new guidance brought out in January 2018, which deemed Avastin as safe and as effective as the licensed anti-VEGFs, and the court case won by the NHS CCGs last week, GlobalData expects that off-label Avastin use will penetrate the UK wet AMD space reducing UK AMD sales share.”

7MM: US, France, Germany, Italy Spain, UK, and Japan

ENDS

For more information

To gain access to our latest press releases: GlobalData Media Centre

Analysts available for comment. Please contact the GlobalData Press Office:

email: pr@globaldata.com

EMEA & Americas: +44 (0)207 832 4399

Asia-Pacific: +91 40 6616 6809

GlobalData.com | LinkedIn | Twitter

Notes to Editors

Comments provided by Dr. Edit Kovalcsik, Cardiovascular and Metabolic Diseases Managing Analyst for GlobalData

Information taken from GlobalData’s Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2026

About GlobalData
4,000 of the world’s largest companies, including over 70% of FTSE 100 and 60% of Fortune 100 companies, make more timely and better business decisions thanks to GlobalData’s unique data, expert analysis and innovative solutions, all in one platform. GlobalData’s mission is to help our clients decode the future to be more successful and innovative across a range of industries, including the healthcare, consumer, retail, financial, technology and professional services sectors. PR2782